Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover trial of bilastine, desloratadine, rupatadine, and placebo on histamine-induced skin reactivity
2015-000790-13Phase 4Completed
- Sponsor
- Faes Farma
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bilastine, desloratadine and rupatadine in allergic rhinoconjunctivitis (ARC) and chronic urticaria (CU) (4 arms), sponsored by Faes Farma. Primary endpoints: Percentage reduction of wheal area and Percentage reduction of flare area. Started May 2015; status: completed.
02
Drugs
bilastinedesloratadinerupatadine
03
Conditions
allergic rhinoconjunctivitis (ARC)chronic urticaria (CU)
Beyond the preview
Go deeper on 2015-000790-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000790-13.